Publication:
Is Azithromycin the first-choice macrolide for treatment of community-acquired pneumonia?

Simple item page
dc.contributor.authorSánchez, F.
dc.contributor.authorMensa, J.
dc.contributor.authorMartínez, J.A.
dc.contributor.authorGarcía-Vázquez, Elisa
dc.contributor.authorMarco, F.
dc.contributor.authorGonzález, J.
dc.contributor.authorMarcos, F.A.
dc.contributor.authorSoriano, A.
dc.contributor.authorTorres, A.
dc.contributor.departmentMedicina
dc.date.accessioned2024-06-19T10:25:56Z
dc.date.available2024-06-19T10:25:56Z
dc.date.issued2003-05-06
dc.description©2003 Infectious Diseases Society of America. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ . This document is the Published, version of a Published Work that appeared in final form in Clinical Infectious Diseases. To access the final edited and published work see https://doi.org/10.1086/374846es
dc.description.abstractCombination treatment with ab-lactam plus a macrolide may improve the outcome for elderly patients with community-acquired pneumonia (CAP). The prognoses and mortality rates for elderly patients with CAP who receive ceftriaxone combined with a 3-day course of azithromycin or a 10-day course of clarithromycin were compared in an open-label, prospective study. Of 896 assessable patients, 220 received clarithromycin and 383 received azithromycin. There were no significant differences between groups with regard to the severity score defined by the Pneumonia Patient Outcomes Research Team (PORT) study group; the incidence of bacteremia was also not significantly different. However, for patients treated with azithromycin, the length of hospital stay was shorter (mean+_ SD, 7.4+_5 vs 9.4+_7 days; P<.01) and the mortality rate was lower (3.6% vs. 7.2%; P<.05); compared with those treated with clarithromycin. There might be a difference in the outcome for patients with CAP depending on the macrolide used. A shorter treatment course with azithromycin may result in better compliance with therapyes
dc.formatapplication/pdfes
dc.format.extent7es
dc.identifier.citationClinical Infectious Diseases. 2003 36:1239–45
dc.identifier.doihttps://doi.org/10.1086/374846
dc.identifier.issnPrint: 1058-4838
dc.identifier.issnElectronic: 1537-6591
dc.identifier.urihttp://hdl.handle.net/10201/142417
dc.languageenges
dc.publisherInfectious Diseases Society of Americaes
dc.relationSin financiación externa de la niversidades
dc.relation.publisherversionhttps://academic.oup.com/cid/article/36/10/1239/307146es
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.accessRightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectCeftriaxonees
dc.subjectAzithromycines
dc.subjectBacteremiaes
dc.subjectCommunity acquired pneumoniaes
dc.subjectClarithromycines
dc.subjectPneumoniaes
dc.subjectMacrolideses
dc.subjectMortalityes
dc.subjectOlder adultes
dc.subjectPostoperativees
dc.subjectRadiotherapyes
dc.subjectPatient-focused outcomeses
dc.titleIs Azithromycin the first-choice macrolide for treatment of community-acquired pneumonia?es
dc.typeinfo:eu-repo/semantics/articlees
dspace.entity.typePublicationes
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Is Azithromycin the First-Choice Macrolide...pdf
Size:
121.64 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.26 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Artículos